🗞️ Why in News The Union Budget 2026-27 allocated Rs 10,000 crore for Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation), aiming to transform India from the “Pharmacy of the World” for generics into a global biologics and biosimilars manufacturing hub.
The Editorial Argument
The Economic Times argues that Biopharma SHAKTI correctly identifies the next frontier for India’s pharmaceutical industry, but success depends on overcoming structural bottlenecks in regulatory speed, research infrastructure, and clinical trial capacity that have kept India at just 3.2% of the global biosimilars market.
The Generics-Biologics Paradox
| Parameter | Generics | Biologics |
|---|---|---|
| Molecule type | Small chemical molecules | Large complex proteins from living cells |
| Replication | Exact copy possible | Only “similar” versions (biosimilars) |
| Manufacturing | Chemical synthesis | Cell culture, fermentation, requires specialised facilities |
| Regulatory pathway | ANDA (abbreviated) | Full analytical + clinical studies needed |
| India’s global share | ~20% | ~3.2% |
| Market size (global) | ~$400 billion | ~$500 billion (growing to $800B by 2030) |
India dominates generics because the pathway is well-established: reverse-engineer the chemical formula, prove bioequivalence, manufacture at scale. Biologics are fundamentally different, they require living cell cultures, cold chain logistics, and extensive clinical validation.
What SHAKTI Proposes
| Component | Detail |
|---|---|
| NIPERs | 3 new + 7 upgraded |
| Clinical trial sites | 1,000+ accredited |
| CDSCO strengthening | Dedicated scientific review cadre |
| Non-animal testing | Shift to 3Rs (Replace, Reduce, Refine) |
| Budget | Rs 10,000 crore |
The Bottlenecks
- Regulatory speed: India’s CDSCO takes 12-18 months for biosimilar approval vs 10 months at the US FDA
- Research talent: India produces abundant pharma graduates but few with biomanufacturing expertise
- Cold chain: Biologics require -20°C to -80°C storage; India’s cold chain infrastructure is inadequate outside metros
- Clinical trial capacity: India conducts only ~3% of global clinical trials despite having 17% of the world’s population
- IP barriers: Many originator biologics are still under patent protection in key markets
Indian Biosimilar Leaders
| Company | Key Biosimilar |
|---|---|
| Biocon | Trastuzumab (breast cancer), Insulin Glargine |
| Dr Reddy’s | Rituximab (blood cancer) |
| Cipla | Adalimumab (autoimmune) |
| Zydus | Pegfilgrastim (neutropenia) |
These companies have achieved US FDA and EMA approvals for biosimilars, proving India can compete, but at a scale far below potential.
Global Context
The biologics revolution is reshaping healthcare:
- Cancer immunotherapy (checkpoint inhibitors), $50+ billion market
- GLP-1 agonists (semaglutide for diabetes and obesity), $40+ billion market
- Gene therapies: emerging, with treatments costing $2-3 million per patient
- mRNA vaccines: proven during COVID, now expanding to cancer and rare diseases
India’s cost advantage, manufacturing at 30-40% lower cost than Western competitors, is a massive opportunity if the regulatory and infrastructure gaps are closed.
UPSC Relevance
Prelims: NIPER Act 1998, CDSCO, DCGI, Drugs and Cosmetics Act 1940, biologics vs biosimilars, 3Rs principle
Mains GS-3: India’s pharmaceutical industry; Make in India for healthcare; S&T policy for economic growth
📌 Facts Corner: Knowledgepedia
Biopharma SHAKTI:
- Full form: Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation
- Budget: Rs 10,000 crore
- NIPERs: 3 new + 7 upgraded (total 10)
- Clinical trial sites: 1,000+
- Non-animal testing: 3Rs principle
India Pharma Industry:
- Global rank: 3rd by volume
- Generics: 20% of global supply
- Vaccines: 60% of global supply
- Biosimilar share: 3.2% globally
- Domestic biosimilars: 95+ approved
- Industry size: ~$50 billion
- Exports: ~$28 billion/year
Global Biologics Market:
- 2025: ~$500 billion
- 2030 (projected): ~$800 billion
- Growth rate: 8-10% annually
- Top companies: Roche, AbbVie, Amgen, J&J
Other Relevant Facts:
- India’s clinical trial share: ~3% of global
- CDSCO approval time: 12-18 months
- US FDA approval: ~10 months
- NIPERs: 7 currently (est. under NIPER Act 1998)
- Indian Pharmacopoeia Commission: sets drug quality standards
Sources: Economic Times, Business Standard
Interview Angle
"India supplies 20% of global generics but only 3.2% of biosimilars. What structural bottlenecks prevent India from replicating its generics success in the biologics space?"
Cite this page: Biopharma SHAKTI, Can India Bridge the Biologics Gap and Become the Next Pharmacy Frontier? — Ujiyari.com | Free UPSC & State PCS Editorial Analysis
